Innate immunity-stroma crosstalk in pancreatic cancer: overcoming spatial and metabolic barriers to immunotherapy
- 1Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University , , ,
Abstract
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to current immunotherapies, a challenge largely attributed to its uniquely immunosuppressive and desmoplastic tumor microenvironment (TME). At the heart of this therapeutic recalcitrance lies the dynamic, bidirectional crosstalk between innate immune cells—particularly tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs)—and stromal components, notably cancer-associated fibroblasts (CAFs). This review comprehensively delineates how the innate immunity-stroma axis establishes formidable spatial and metabolic barriers that thwart effective antitumor immunity. Spatially, dense collagen matrices, periductal fibroblast organization, and neutrophil extracellular traps (NETs) create physical checkpoints that exclude cytotoxic CD8+ T cells and natural killer (NK) cells from tumor nests. Metabolically, elevated lactate, cholesterol dysregulation, adenosine accumulation, and altered polyamine metabolism synergistically paralyze effector lymphocytes while driving immunosuppressive myeloid polarization. We highlight the key molecular networks orchestrating this pathological crosstalk, including the NF-κB, IL-1β, JAK/STAT3, and TGF-β signaling pathways. Furthermore, we summarize emerging therapeutic strategies designed to dismantle these barriers, encompassing macrophage reprogramming, CAF modulation, and metabolic interventions. Finally, we discuss the multidimensional “3D+R” framework—integrating de-desmoplasia, de-adenosine, de-novo antigen presentation, and rational sequencing—as a conceptual roadmap for rationally designed combination therapies to overcome PDAC immunotherapy resistance.
Related
- CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
- Decoding lipid metabolic reprogramming in pancreatic ductal adenocarcinoma: from tumor–microenvironment crosstalk to therapeutic resistance
- Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery
- Editorial: Community series in unveiling the next generation of cancer immunity & immunotherapy in lung cancer, volume II
- Strategic engineering B cell immunity for cancer immunotherapy
BibTeX
@article{hou2026innate,
title = {{Innate immunity-stroma crosstalk in pancreatic cancer: overcoming spatial and metabolic barriers to immunotherapy}},
author = {Yulong Hou and Zhenhua Tan},
journal = {Frontiers in immunology},
year = {2026},
month = sep,
doi = {10.3389/fimmu.2026.1942345},
url = {https://europepmc.org/article/PMC/PMC13662915},
note = {CC BY},
}
RIS
TY - JOUR
TI - Innate immunity-stroma crosstalk in pancreatic cancer: overcoming spatial and metabolic barriers to immunotherapy
AU - Yulong Hou
AU - Zhenhua Tan
PY - 2026
DA - 2026/09/30
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1942345
UR - https://europepmc.org/article/PMC/PMC13662915
AB - Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to current immunotherapies, a challenge largely attributed to its uniquely immunosuppressive and desmoplastic tumor microenvironment (TME). At the heart of this therapeutic recalcitrance lies the dynamic, bidirectional crosstalk between innate immune cells—particularly tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs)—and stromal components, notably cancer-associated fibroblasts (CAFs). This review comprehensively delineates how the innate immunity-stroma axis establishes formidable spatial and metabolic barriers that thwart effective antitumor immunity. Spatially, dense collagen matrices, periductal fibroblast organization, and neutrophil extracellular traps (NETs) create physical checkpoints that exclude cytotoxic CD8+ T cells and natural killer (NK) cells from tumor nests. Metabolically, elevated lactate, cholesterol dysregulation, adenosine accumulation, and altered polyamine metabolism synergistically paralyze effector lymphocytes while driving immunosuppressive myeloid polarization. We highlight the key molecular networks orchestrating this pathological crosstalk, including the NF-κB, IL-1β, JAK/STAT3, and TGF-β signaling pathways. Furthermore, we summarize emerging therapeutic strategies designed to dismantle these barriers, encompassing macrophage reprogramming, CAF modulation, and metabolic interventions. Finally, we discuss the multidimensional “3D+R” framework—integrating de-desmoplasia, de-adenosine, de-novo antigen presentation, and rational sequencing—as a conceptual roadmap for rationally designed combination therapies to overcome PDAC immunotherapy resistance.
SN - 1664-3224
ER -